指南与共识医学教育与科研方法流行病学与生物统计

将减药建议纳入临床实践指南的障碍与促进因素:一项定性研究

Barriers and enablers to integrating deprescribing recommendations into clinical practice guidelines: a qualitative study.
指南 / 共识 · J Clin Epidemiol · 2026-09-10

本研究通过半结构化访谈探讨将循证减药建议整合进临床实践指南的障碍与促进因素。共访谈25名指南制定者及关键利益相关者,分析得出10个主题和34个亚主题,涵盖障碍与促进因素。减药建议与指南目标一致,但需从指南范围设定之初即纳入并克服后勤障碍。

要点

  • 减药建议与指南改善患者结局、减少伤害的目标一致
  • 障碍包括对减药的认识不足、证据强度不确定及时间资源限制
  • 需提供方法学支持并探索终端用户对减药建议内容与格式的偏好

核心结论

  • 将减药建议纳入临床实践指南与指南目标一致,但确保从指南范围设定之初即纳入及克服后勤障碍仍是挑战。

研究设计与样本

  • 定性研究,采用半结构化访谈,通过目的性抽样国际招募指南制定者(主席、方法学家、临床医生、消费者)及支持指南制定组织的关键利益相关者。
  • 共访谈25名参与者,包括18名指南制定者(11名参与治疗指南,7名参与以减药为重点的指南)和7名关键利益相关者。

主要发现

  • 分析揭示10个主题和34个亚主题,涵盖障碍、促进因素或两者兼有。
  • 主题包括对减药的态度与知识、与指南目标的一致性、与其它照护举措的一致性、内部与外部对指南范围的影响、后勤考虑、证据、建议组成、实施考虑及潜在后果。

临床怎么用

  • 可考虑为指南制定者提供方法学支持,并探索终端用户对减药建议内容、语言和格式的偏好以促进指南实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the barriers and enablers to integrating evidence-based deprescribing recommendations into clinical practice guidelines. STUDY DESIGN AND SETTING: Qualitative semi-structured interviews were conducted with guideline developers (including chairs, methodologists, clinicians, and consumers) and key interest-holders from organizations supporting guideline development. Participants were recruited internationally, through purposive sampling via professional organizations, conference promotion, personal networks, social media, snowball sampling, and direct contact with individuals identified from publicly available guideline records. The interviews were audiotaped, transcribed, and analyzed using inductive conventional content analysis. RESULTS: A total of 25 participants were interviewed, comprising 18 guideline developers (n = 11 involved in treatment guidelines; n = 7 involved in deprescribing-focused guidelines) and seven key interest-holders. Participants had experience developing guidelines across regions including Australasia, North America, and Europe, with involvement ranging from a single guideline to more than 10. The analysis revealed 10 themes and 34 subthemes, encompassing barriers, enablers, or both. The themes included (1) attitudes and knowledge of deprescribing; (2) alignment with the goals of guidelines; (3) alignment with other care initiatives; (4) internal influence on guideline scope; (5) external influence on guideline scope; (6) logistical considerations; (7) evidence to inform recommendations; (8) deprescribing recommendation components; (9) implementation considerations; and (10) potential consequences. CONCLUSION: The inclusion of deprescribing recommendations in clinical practice guidelines aligns with the goals of guidelines. However, challenges remain such as ensuring its inclusion within the guideline scope from the outset and overcoming logistical barriers. Further consultation and research are needed to determine how best to leverage potential enablers. This may include providing methodological support for guideline developers and exploring end-users' preferences for the content, language, and format of deprescribing recommendations to enhance guideline implementation in practice. PLAIN LANGUAGE SUMMARY: This study explored what helps or hinders the inclusion of deprescribing recommendations (guidance on when and how to reduce or stop medications) within clinical practice guidelines. Although deprescribing is increasingly recognized as an important part of safe and effective care, many existing guidelines provide limited direction on how to approach it. Understanding why deprescribing guidance is not routinely included, and what might support its integration, is important for improving patient care. To investigate this, we conducted in-depth interviews with people involved in developing clinical practice guidelines. Participants included guideline chairs, guideline methods experts, clinicians, consumer representatives, and individuals from organizations that support guideline development. They were recruited internationally through professional networks, conferences, social media, and publicly available guideline records. Interviews were recorded, transcribed, and analyzed to identify common themes. We interviewed 25 people from regions including Australasia, North America, and Europe. Eighteen were guideline developers, and seven were individuals with a broader interest in guidelines. Their experience ranged from contributing to a single guideline to working on more than 10. From the interviews, we identified 10 major themes and 34 subthemes describing both barriers and enablers to integrating deprescribing into guidelines. Participants agreed that deprescribing fits well with the overall goals of guidelines, such as improving patient outcomes and reducing harm. Challenges included limited awareness or understanding of deprescribing, uncertainty about the strength or type of evidence needed to support deprescribing recommendations, and practical constraints such as time, resources, and the complexity of guideline development processes. External influences, including expectations from regulators or other interested groups, also shaped what could be included. Opportunities to strengthen deprescribing guidance included clearer recommendations, better alignment with other efforts to improve care, and practical resources to support routine use. Overall, the study shows that while deprescribing fits naturally within the purpose of guidelines, practical and structural barriers can limit its inclusion. Further work is needed to support guideline developers, strengthen the evidence base, and understand what healthcare professionals and consumers need to make deprescribing recommendations more useful in everyday practice.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Liau SJ, Mill D, McEvoy AM, et al. Barriers and enablers to integrating deprescribing recommendations into clinical practice guidelines: a qualitative study. J Clin Epidemiol. 2026. PMID: 42716451. doi:10.1016/j.jclinepi.2026.112502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。